Key result
Uninterrupted use of novel oral anticoagulants and vitamin K antagonists is a safe and effective strategy for minimizing thromboembolic and bleeding risks during atrial fibrillation ablation.
Why the study?
Does periprocedural oral anticoagulation prevent stroke and minimize bleeding in patients undergoing atrial fibrillation ablation?
Does periprocedural oral anticoagulation prevent stroke and minimize bleeding in patients undergoing atrial fibrillation ablation?
Uninterrupted oral anticoagulation, including NOACs, is a safe and effective strategy for managing stroke and bleeding risks during atrial fibrillation ablation.
Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice today. For those who present with it, one of the most major risks associated with the condition is stroke. AF is associated with a fivefold increased risk of stroke and thromboembolism. Oral anticoagulation has been the cornerstone of stroke prevention in patients with AF. In some individuals who exhibit a higher risk of bleeding, other alternatives for stroke prevention have been sought, including the use of left atrial appendage occlusion devices and surgical exclusion of the left atrial appendage. Catheter ablation is an important treatment strategy in those patients for whom a rhythm control strategy has been selected. This article reviews some of the available anticoagulant drug options and their use prior to, during, and after catheter ablation.
No takes yet. Share an insight, caveat, or question.
Maraj et al. (2018) conducted a review in Atrial Fibrillation. Oral Anticoagulation Therapy (NOACs and VKAs) was evaluated. Uninterrupted use of novel oral anticoagulants and vitamin K antagonists is a safe and effective strategy for minimizing thromboembolic and bleeding risks during atrial fibrillation ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: